Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01765179 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Trial of Testosterone Undecanoate
A Phase 3 study of Male Hypogonadism, sponsored by Clarus Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 144
- Enrollment target
- 20
- Study locations
NCT01765179: Completed Phase 3 study of Male Hypogonadism, sponsored by Clarus Therapeutics.
NCT01765179 is a Phase 3 study of Male Hypogonadism that has completed, run by Clarus Therapeutics. The registered enrollment target is 144 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01765179, a Phase 3 study of Male Hypogonadism, has completed, sponsored by Clarus Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 144 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to determine if oral testosterone undecanoate is effective and safe in the treatment of low testosterone in men.
Primary Outcome
The number of subjects (116) analyzed includes only those subjects with serum testosterone Cavg data available on study day 114.
Conditions Studied
Interventions
- DRUG Oral testosterone undecanoate
Study Locations (20)
California
- SC Clinical Research, Inc. - Garden Grove
- South ORange County Endocrinology - Laguna Hill
- Tower Urology, Tower Research Institute - Los Angeles
- San Diego Sexual Medicine - San Diego
- LABiomedical Research Institute at Harbor-UCLA Medical Center - Torrance
Arizona
- Precision Trials/Valley Urologic Associates - Glendale
- Premier Clinical Research Center - Phoenix
- Precision Trials/Valley Urologic Associates - Phoenix
- Quality of LIfe Medical and Research Center - Tucson
Florida
- South Florida Medical Research - Aventura
- PAB Clinical Research - Brandon
- Innovative Research of West Florida - Clearwater
- Jacksonville Impotence Treatment Center - Jacksonville
Alabama
- Alabama Clinical Therapeutics, LLC - Birmingham
- Alabama Internal Medicine, PC - Birmingham
- Medical Affliated Research Center, Inc. - Huntsville
Connecticut
- Conneticut Clinical Research Center - Middlebury
New York
- University Urology Associates - New York
Oregon
- Sunstone Medical Research - Medford
Pennsylvania
- Unrologic Consultants of SE Pennsylvania - Bala-Cynwyd
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2013-01 |
| Est. Completion | 2013-07 |
| Phase | Phase 3 |
What the finished NCT01765179 record still lists
NCT01765179 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Male Hypogonadism appearing as the primary indexed condition, and to 1 intervention - of which Oral testosterone undecanoate is the first listed.
NCT01765179 names 20 study sites across 8 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT01765179 about?
NCT01765179 is a clinical study titled "Safety and Efficacy Trial of Testosterone Undecanoate". The purpose of the study is to determine if oral testosterone undecanoate is effective and safe in the treatment of low testosterone in men.
What is the current status of trial NCT01765179?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 144 participants. The study started on 2013-01. Estimated completion is 2013-07.
What conditions does trial NCT01765179 study?
This clinical trial studies the following conditions: Male Hypogonadism.
What interventions are being tested in trial NCT01765179?
The interventions under investigation include: Oral testosterone undecanoate (DRUG).
Who is sponsoring clinical trial NCT01765179?
This trial is sponsored by Clarus Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01765179 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Male Hypogonadism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01765179's enrollment target sits among peer trials
144 1559th of 2000 higher than 442 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia